GlassScriptPhysician profile
Ningxi Zhu
NPI 1487948121
$12,229.45
in general payments reported to CMS, 2019-2025
37 companies · $2,402 in 2025
The $2,402 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $590 · 2021: $1,026 · 2022: $2,172 · 2023: $2,256 · 2024: $2,509 · 2025: $2,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,166.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,623.40 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,384.55 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $895.30 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $733.27 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $708.32 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $667.81 | 2019-2025 | Xolair |
| Csl Behring | $538.08 | 2019-2023 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $402.09 | 2019-2025 | |
| Galderma Laboratories, L.P. | $385.61 | 2024-2025 | Nemluvio |
| Abbvie INC. | $287.20 | 2022-2025 | Rinvoq |
| Alk-Abello, INC | $276.20 | 2019-2022 | |
| Kaleo, INC. | $259.70 | 2022-2024 | Auvi-Q |
| Amgen INC. | $242.09 | 2021-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $188.83 | 2023 | |
| Octapharma USA, INC. | $186.62 | 2021-2025 | Cutaquig |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $179.57 | 2019-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $173.34 | 2020-2025 | Cuvitru |
| Horizon Therapeutics Plc | $147.51 | 2019-2021 | |
| Optinose US, INC. | $116.43 | 2020-2025 | |
| Incyte Corporation | $97.79 | 2021-2022 | |
| Blueprint Medicines Corporation | $95.02 | 2023-2024 | Ayvakit |
| Grifols USA, LLC | $88.58 | 2023-2025 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.72 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $71.18 | 2025 | Voquezna |
| Pfizer INC. | $59.58 | 2022-2023 | |
| Ars Pharmaceuticals Operations, INC. | $59.09 | 2025 | Neffy |
| Organon LLC | $58.69 | 2025 | |
| Hikma Pharmaceuticals USA | $50.55 | 2022-2025 | Ryaltris |
| Sunovion Pharmaceuticals INC. | $29.49 | 2019 | |
| Lilly USA, LLC | $28.80 | 2025 | Ebglyss |
| Biocryst US Sales Co., LLC | $21.09 | 2021 | |
| Cycle Pharmaceuticals INC | $16.07 | 2025 | Sajazir |
| Teva Pharmaceuticals USA, INC. | $15.38 | 2021 | |
| Arcutis Biotherapeutics, INC. | $15.00 | 2025 | Zoryve |
| Leo Pharma INC. | $14.78 | 2024 | Adbry |
| Phadia US INC. | $13.88 | 2024 | Immunocap |
| Covis Pharma Gmbh | $12.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ningxi Zhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.